Explore the latest in lung cancer, including advances in understanding epidemiology, risk factors, treatment biomarkers, and management.
This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.
This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.
This secondary analysis of a randomized clinical trial examines the association of modern chemoradiotherapy with survival among patients with stage I to II small cell lung cancer compared with that among patients with stage III small cell lung cancer.
This JAMA Clinical Guidelines Synopsis summarizes the 2017 Fleischner Society guidelines on management of incidental pulmonary nodules detected on computed tomography (CT) imaging.
This cohort study investigates the association between radiation doses in the parotid glands and self-reported xerostomia among adults treated with whole-brain radiation therapy.
This case report describes an unusual case of hyperhidrosis associated with apical lung cancer with sympathetic nerve involvement.
This population-based study compares opioid use in patients with non–small cell lung cancer who underwent open resection vs video-assisted thoracoscopic surgery.
This cohort study examines mechanisms of acquired resistance to osimertinib in patients with non–small cell lung cancer and the associated clinical implications.
This randomized clinical trial examines the efficacy of anlotinib compared with placebo as a third-line or further therapy on overall survival of adult patients with advanced non–small cell lung cancer.
This multicenter cohort study investigates whether hyperprogressive disease is observed in patients with advanced non–small cell lung cancer treated with programmed cell death 1 and programmed cell death ligand 1 inhibitors compared with single-agent chemotherapy.
This Viewpoint discusses the role of prophylactic cranial irradiation in small cell lung cancer in the current setting of active surveillance via magnetic resonance imaging.
This prognostic study develops and validates a nomogram to assess the probability of survival at 3, 6, and 12 months in patients from Taiwan with metastatic lung cancer who were referred for radiotherapy to treat osseous metastases.
This validation study investigates the use of circulating protein biomarkers to improve lung cancer risk assessment and eligibility criteria for screening with low-dose computed tomography.
This study assesses whether plasma-based next-generation sequencing was associated with improved mutation detection and enhanced delivery of personalized therapy in a real-world clinical setting of patients with non–small cell lung cancer.
An HIV-positive man in his 30s being treated with pembrolizumab for metastatic programmed cell death ligand 1–positive squamous non–small cell lung cancer presents with pruritic, mildly painful, hyperpigmented papules and plaques on both feet. What is your diagnosis?
This commentary discusses a cohort study of patients with non–small cell lung cancer published in JAMA that compares clinical outcomes following broad-based genomic sequencing vs routine testing for EGFR mutations and/or ALK mutations.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: